Science Current Events | Science News | Brightsurf.com
 
Email a Friend Send to a friend
Printer Friendly Print Study implicates defective synapse generator in onset of Alzheimer's

Study implicates defective synapse generator in onset of Alzheimer's

January 27, 2006

Finding links age-related brain disease to Down syndrome

A new UCLA/Veterans Affairs study implicates defects in the machinery that creates connections between brain cells as responsible for the onset of Alzheimer disease.




The defect in PAK enzyme signaling pathways - vital to creation of these connections, or synapses - is related to loss of a synapse protein in certain forms of mental retardation, such as Down syndrome. The new finding suggests therapies designed to address the PAK defect could treat cognitive problems in both patient populations.

The peer-reviewed journal Nature Neuroscience published the study online Jan. 15.

"The emerging lesson is that cognitive problems in Alzheimer disease are related to defects in the machinery controlling neuronal connections, not the lesions observed by pathologists," said principal investigator Greg Cole, professor of medicine and neurology at the David Geffen School of Medicine and Alzheimer Disease Research Center at UCLA, and the Geriatric Research Education and Clinical Center at the Veterans Affairs Greater Los Angeles Health Care System and Sepulveda Ambulatory Care Center. "Our findings show that PAK defects in the brains of Alzheimer patients appear sufficient to directly cause cognitive difficulties."

In some families, early-onset Alzheimer disease can be caused by mutations in different genes that all increase the production of a sticky protein called Abeta42 (Ab42). The increase causes the protein to form aggregates, little clusters or long filaments that pile up and make lesions in the brain called plaques.

Ab42 is widely believed to cause Alzheimer, but the process remains unclear. Soluble Ab42 aggregates called "oligomers" are now considered as a major toxic form of Ab42 and therefore implicated in loss of synapses and memory.

This new study implicates the PAK enzyme-signaling pathway, which is known to play a role in synapse formation and developmental cognitive deficits, or mental retardation.

The PAK enzymes form a family that includes two members known to localize to synapses (PAK1 and PAK3). Both are known to play critical roles in learning and memory. Humans with genetic loss of PAK3 have severe mental retardation. Both PAK1 and PAK3 are abnormally distributed and reduced in Alzheimer patients to an extent sufficient to contribute to cognitive decline.

The research team finds that blocking these PAKs in middle-aged mice causes memory loss together with deficits in a protein involved in making neuronal connections. In humans, the same protein shows large losses in Alzheimer as well as in Down syndrome, the most common cause of mental retardation.

The study also shows in cultures and animal models that Ab42 oligomers induce defects in PAK similar to those seen in Alzheimer disease, and selective loss of the same neuronal connection protein lost in Alzheimer disease and Down syndrome. The findings suggest PAK loss in Alzheimer brains is sufficient to directly cause these cognitive deficits.

University of California-Los Angeles



Related Alzheimer Disease Current Events and Alzheimer Disease News Articles Alzheimer Disease Current Events and Alzheimer Disease News RSS Alzheimer Disease Current Events and Alzheimer Disease News RSS
Delirium in hospitalized adults: Situation critical, no relief available
Every year as many as seven million adults in the United States experience delirium during hospitalization.

New data demonstrate potential for early detection of Alzheimer's disease
Data published in the June issue of the Journal of Alzheimer's Disease demonstrated that minimally-invasive biospectroscopy was able to identify changes in oxidative stress (OS) levels in blood plasma, which may prove to be a useful biomarker in the early detection of Alzheimer's disease.

Another McGill/JGH breakthrough opens door to early Alzheimer's diagnosis
A new diagnostic technique which may greatly simplify the detection of Alzheimer's disease has been discovered by researchers at McGill University and the affiliated Lady Davis Institute for Medical Research at Montreal's Jewish General Hospital (JGH).

Measuring brain atrophy in patients with mild cognitive impairment
Scientists at the University of California, San Diego School of Medicine have shown that a fully automated procedure called Volumetric MRI - which measures the "memory centers" of the brain and compares them to expected size - is effective in predicting the progression from mild cognitive impairment (MCI) to Alzheimer's disease.

Commonly used medications may produce cognitive impairment in older adults
Many drugs commonly prescribed to older adults for a variety of common medical conditions including allergies, hypertension, asthma, and cardiovascular disease appear to negatively affect the aging brain causing immediate but possibly reversible cognitive impairment, including delirium, in older adults.

Commonly used ulcer drugs may offer treatment potential in Alzheimer's disease
In a new study, published in the May issue of Elsevier's Experimental Neurology, scientists at the University of British Columbia have discovered that drugs commonly used to treat ulcers have significant neuroprotective properties, which appear to be enhanced when used in combination with ibuprofen, a widely used anti-inflammatory drug.

New test for mysterious metabolic diseases developed at Stanford/Packard
Scientists at Stanford University School of Medicine have devised a much-needed way to monitor and find treatments for a mysterious and devastating group of metabolic diseases that arise from mutations in cells' fuel-burning mechanism.

Recalibrating 'fight or flight'
A Canadian/U.S. research team has reported a novel approach to stimulating recovery from chronic stress disorders. Details of the therapeutic model, which exploits the natural dynamics of the body's "fight or flight" system, are published January 23 in the open-access journal PLoS Computational Biology

Vitamin B does not slow cognitive decline in Alzheimer's
A clinical trial led by Paul S. Aisen, M.D., professor of neurosciences at the University of California, San Diego School of Medicine, showed that high-dose vitamin B supplements did not slow the rate of cognitive decline in patients with mild to moderate Alzheimer disease.

Protecting patient privacy the new fashioned way
Protecting patient privacy has been recognized as the duty of health-care providers for about as long as doctors have seen patients. In 1996 that duty became a legal obligation when Congress passed the Health Insurance Portability and Accountability Act.
More Alzheimer Disease Current Events and Alzheimer Disease News Articles
A Caregiver's Guide to Alzheimer's Disease: 300 Tips for Making Life Easier

A Caregiver's Guide to Alzheimer's Disease: 300 Tips for Making Life Easier
by Patricia R. Callone (Editor)

Written for patients, their families, and caregivers, the practical information here will help readers understand what is physically happening to the brain so they can empower their own special skills and talents throughout the disease process. The book is divided into three sections that correspond to the progression of Alzheimer’s, and the unique challenges encountered at each stage.

*Section A: The four stages of Alzheimer's with hundreds of practical tips for coping at each level

*Section B: Q&A for caregivers, including legal and financial issues, medication, helping children understand, handling the holidays and more.

*Section C: Resources and websites.

This is an essential book for all those who want to focus on the capabilities that...

Learning to Speak Alzheimer's: A Groundbreaking Approach for Everyone Dealing with the Disease

Learning to Speak Alzheimer's: A Groundbreaking Approach for Everyone Dealing with the Disease
by Joanne Koenig Coste (Author), Robert Butler (Foreword)

More than four million Americans suffer from Alzheimer’s, and as many as twenty million have close relatives or friends with the disease. Revolutionizing the way we perceive and live with Alzheimer’s, Joanne Koenig Coste offers a practical approach to the emotional well-being of both patients and caregivers that emphasizes relating to patients in their own reality. Her accessible and comprehensive method, which she calls habilitation, works to enhance communication between carepartners and patients and has proven successful with thousands of people living with dementia. Learning to Speak Alzheimer’s also offers hundreds of practical tips, including how to · cope with the diagnosis and adjust to the disease’s progression · help the patient talk about the illness · face the...

Alzheimer's Disease: Facing the Facts

Alzheimer's Disease: Facing the Facts
Starring: n/a
Directed By: n/a

Studio: Wgbh Wholesale Release Date: 03/17/2009 Run time: 56 minutes

My Journey into Alzheimer's Disease

My Journey into Alzheimer's Disease
by Robert Davis (Author)

A book of encouragement of how one man of faith faced the oncoming darkness of Alzheimer's disease. In a powerful story of courage and faith, Davis shows how God gives strength and grace.

  Journal of Alzheimers Disease
by Ios Press



The Alzheimer's Action Plan: What You Need to Know--and What You Can Do--about Memory Problems, from Prevention to Early Intervention and Care

The Alzheimer's Action Plan: What You Need to Know--and What You Can Do--about Memory Problems, from Prevention to Early Intervention and Care
by P. Murali Doraiswamy M.D. (Author), Lisa P. Gwyther M.S.W. (Author), Tina Adler (Author)

What would you do if your mother was having memory problems?

Five million Americans have Alzheimer’s disease, with a new diagnosis being made every seventy-two seconds, with millions more at risk. Although experts agree that early diagnosis and treatment are essential, families don’t know where to turn for authoritative, state-of-the-art advice and answers to all of their questions.

Now, combining the insights of a world-class physician and an award-winning social worker, this ground-breaking book tells you everything you need to know, including:

The best tests to determine if this is—or is not—Alzheimer’s disease...

FlameEz-Memory, 60 Capsules/Bottle

FlameEz-Memory, 60 Capsules/Bottle
by FlameEz

Memory loss is caused by a condition in which cells of the brain are damaged or lost. Dementia and Alzheimer's disease are the common disorders that cause memory loss. Studies have shown that neuron damage begins long before an individual experiences any symptoms and the symptoms are only recognized when many cells have died and the brains can no longer function properly. Unlike many cells in the rest of the body, neurons are not readily regenerated. For this reason, memory loss is a progressive condition that only gets worse, there is no coming back from it. Advanced science has shown critical role of inflammation in Alzheimer's and neurodegenerative diseases. When the brain is injured or infected, cells in the brain called microglia produce inflammatory cytokines. Normally, this...

Alzheimer's Disease & Other Dementias [VHS]

Alzheimer's Disease & Other Dementias [VHS]
Directed By: Mark Julian Campbell



Part 1: Alzheimer's and Related Dementia

Part 1: Alzheimer's and Related Dementia
Directed By: Matt Connolly
Also With: H. Diane Connolly (Producer)



Caring for the Caregiver -- A Guide to Living with Alzheimer's Disease

Caring for the Caregiver -- A Guide to Living with Alzheimer's Disease

171 pages

© 2009 BrightSurf.com